Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611488 | 0.88 | MAPK7 (0.48) | MAPK7KDM4EMAPTTHRBGPR119 | |
| SCHEMBL21332047 | 0.87 | MAPK7 (0.64) | MAPK7KDM4EMAPTTHRBGPR119 | |
| SCHEMBL21339642 | 0.84 | MAPK7 (0.65) | MAPK7KDM4EMAPTTHRBGPR119 | |
| SCHEMBL29611125 | 0.82 | MAPK7 (0.54) | MAPK7KDM4EMAPTTHRBGPR119 | |
| SCHEMBL21339727 | 0.81 | MAPK7 (0.53) | MAPK7SLC2A1SIGMAR1 | |
| SCHEMBL17398314 | 0.79 | KDM4E (0.48) | KDM4EMAPTTHRBGPR119HPGDS | |
| SCHEMBL3568241 | 0.77 | MAPK7 (0.52) | MAPK7KDM4EMAPTTHRBGPR119 | |
| SCHEMBL21332138 | 0.77 | MAPK7 (0.62) | MAPK7KDM4EMAPTTHRBGPR119 | |
| SCHEMBL19297216 | 0.76 | GPR119 (0.50) | MAPK7KDM4EMAPTTHRBGPR119 | |
| SCHEMBL12740695 | 0.76 | GPR119 (0.61) | KDM4EMAPTTHRBGPR119HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017174-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-21 | — | — | US | disclosed |
| EP-3762379-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019170543-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019170543-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017174-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITOR | MAPK15, MAPKAPK5, MAP3K5 | MAPK7 22/4885KDM4E 2409/4885MAPT 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.